Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Detoxified synthetic bacterial membrane vesicles as a vaccine platform against bacteria and SARS-CoV-2

Park, Kyong-Su ; Svennerholm, Kristina ; Crescitelli, Rossella ; Lässer, Cecilia ; Gribonika, Inta LU orcid ; Andersson, Mickael ; Boström, Jonas LU ; Alalam, Hanna ; Harandi, Ali M and Farewell, Anne , et al. (2023) In Journal of Nanobiotechnology 21(1). p.156-156
Abstract

The development of vaccines based on outer membrane vesicles (OMV) that naturally bud off from bacteria is an evolving field in infectious diseases. However, the inherent inflammatory nature of OMV limits their use as human vaccines. This study employed an engineered vesicle technology to develop synthetic bacterial vesicles (SyBV) that activate the immune system without the severe immunotoxicity of OMV. SyBV were generated from bacterial membranes through treatment with detergent and ionic stress. SyBV induced less inflammatory responses in macrophages and in mice compared to natural OMV. Immunization with SyBV or OMV induced comparable antigen-specific adaptive immunity. Specifically, immunization with Pseudomonas aeruginosa-derived... (More)

The development of vaccines based on outer membrane vesicles (OMV) that naturally bud off from bacteria is an evolving field in infectious diseases. However, the inherent inflammatory nature of OMV limits their use as human vaccines. This study employed an engineered vesicle technology to develop synthetic bacterial vesicles (SyBV) that activate the immune system without the severe immunotoxicity of OMV. SyBV were generated from bacterial membranes through treatment with detergent and ionic stress. SyBV induced less inflammatory responses in macrophages and in mice compared to natural OMV. Immunization with SyBV or OMV induced comparable antigen-specific adaptive immunity. Specifically, immunization with Pseudomonas aeruginosa-derived SyBV protected mice against bacterial challenge, and this was accompanied by significant reduction in lung cell infiltration and inflammatory cytokines. Further, immunization with Escherichia coli-derived SyBV protected mice against E. coli sepsis, comparable to OMV-immunized group. The protective activity of SyBV was driven by the stimulation of B-cell and T-cell immunity. Also, SyBV were engineered to display the SARS-CoV-2 S1 protein on their surface, and these vesicles induced specific S1 protein antibody and T-cell responses. Collectively, these results demonstrate that SyBV may be a safe and efficient vaccine platform for the prevention of bacterial and viral infections.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Mice, Animals, Humans, SARS-CoV-2, Escherichia coli, COVID-19/prevention & control, Bacteria, Vaccines, Bacteremia, Escherichia coli Infections/prevention & control, Bacterial Outer Membrane Proteins, Antibodies, Bacterial
in
Journal of Nanobiotechnology
volume
21
issue
1
pages
156 - 156
publisher
BioMed Central (BMC)
external identifiers
  • scopus:85159713761
  • pmid:37208676
ISSN
1477-3155
DOI
10.1186/s12951-023-01928-w
language
English
LU publication?
no
additional info
© 2023. The Author(s).
id
b344a911-cfcd-45c0-b188-e15f70d21a9c
date added to LUP
2025-12-20 13:26:21
date last changed
2025-12-22 15:17:39
@article{b344a911-cfcd-45c0-b188-e15f70d21a9c,
  abstract     = {{<p>The development of vaccines based on outer membrane vesicles (OMV) that naturally bud off from bacteria is an evolving field in infectious diseases. However, the inherent inflammatory nature of OMV limits their use as human vaccines. This study employed an engineered vesicle technology to develop synthetic bacterial vesicles (SyBV) that activate the immune system without the severe immunotoxicity of OMV. SyBV were generated from bacterial membranes through treatment with detergent and ionic stress. SyBV induced less inflammatory responses in macrophages and in mice compared to natural OMV. Immunization with SyBV or OMV induced comparable antigen-specific adaptive immunity. Specifically, immunization with Pseudomonas aeruginosa-derived SyBV protected mice against bacterial challenge, and this was accompanied by significant reduction in lung cell infiltration and inflammatory cytokines. Further, immunization with Escherichia coli-derived SyBV protected mice against E. coli sepsis, comparable to OMV-immunized group. The protective activity of SyBV was driven by the stimulation of B-cell and T-cell immunity. Also, SyBV were engineered to display the SARS-CoV-2 S1 protein on their surface, and these vesicles induced specific S1 protein antibody and T-cell responses. Collectively, these results demonstrate that SyBV may be a safe and efficient vaccine platform for the prevention of bacterial and viral infections.</p>}},
  author       = {{Park, Kyong-Su and Svennerholm, Kristina and Crescitelli, Rossella and Lässer, Cecilia and Gribonika, Inta and Andersson, Mickael and Boström, Jonas and Alalam, Hanna and Harandi, Ali M and Farewell, Anne and Lötvall, Jan}},
  issn         = {{1477-3155}},
  keywords     = {{Mice; Animals; Humans; SARS-CoV-2; Escherichia coli; COVID-19/prevention & control; Bacteria; Vaccines; Bacteremia; Escherichia coli Infections/prevention & control; Bacterial Outer Membrane Proteins; Antibodies, Bacterial}},
  language     = {{eng}},
  month        = {{05}},
  number       = {{1}},
  pages        = {{156--156}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Journal of Nanobiotechnology}},
  title        = {{Detoxified synthetic bacterial membrane vesicles as a vaccine platform against bacteria and SARS-CoV-2}},
  url          = {{http://dx.doi.org/10.1186/s12951-023-01928-w}},
  doi          = {{10.1186/s12951-023-01928-w}},
  volume       = {{21}},
  year         = {{2023}},
}